RxDoctor Payments DataLook up a doctor →

Scott Wilson, MD

Internal Medicine · Cumberland, RINPI 1619974672

Payments from drug & device makers

$906,889in general payments, 2019–2025

Across 921 payments — averaging $984.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737K
  • Ironwood Pharmaceuticals, Inc$68K
  • Noven Pharmaceuticals, Inc.$38K
  • Esperion Therapeutics, Inc.$22K
  • Eli Lilly$17K
  • Novo Nordisk AS$10K
  • plus $14K from 48 others
$4,225in research payments, 2019–2025

Across 6 payments — averaging $704.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)244$736,947
Ironwood Pharmaceuticals, Inc10$67,836
Noven Pharmaceuticals, Inc.25$38,264
Esperion Therapeutics, Inc.42$21,949
Eli Lilly8$17,240
Novo Nordisk AS194$10,265
Chiesi USA, Inc.1$6,550
AstraZeneca53$1,016
Pfizer61$759
GSK28$502
Amgen24$477
Lilly USA, LLC25$466
Mylan Specialty L.p.20$427
Astellas Pharma US Inc12$399
Vanda Pharmaceuticals Inc.12$381
Novo Nordisk17$354
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$230
Johnson & Johnson12$221
Exact Sciences8$200
Abbott9$198
Aimmune Therapeutics, Inc.8$187
Novartis5$175
Exeltis, USA Inc.1$166
Tolmar, Inc.8$149
Verity Pharmaceuticals Inc.4$131
Merck7$124
Paratek Pharmaceuticals, Inc.6$115
E.r. Squibb & Sons, L.L.C.6$98
Dexcom, Inc.4$91
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$82
Melinta Therapeutics, LLC4$75
Teva Pharmaceuticals USA, Inc.5$74
Verona Pharma, Inc.2$60
Currax Pharmaceuticals LLC4$58
Lundbeck LLC3$54
Sumitomo Pharma America, Inc.2$54
Otsuka America Pharmaceutical, Inc.2$49
Almatica Pharma LLC2$49
Boehringer Ingelheim2$44
Takeda Pharmaceuticals U.S.A., Inc.6$41
Regeneron Healthcare Solutions, Inc.2$37
Bayer2$36
Amarin Pharma, Inc.2$34
Lucid Diagnostics Inc.2$28
Supernus Pharmaceuticals, Inc.1$24
Phathom Pharmaceuticals, Inc.1$23
Halozyme Inc1$23
Shire North American Group Inc1$21
Xeris Pharmaceuticals, Inc.1$19
Sanofi Pasteur Inc.1$19
Collegium Pharmaceutical, Inc.1$18
Amneal Pharmaceuticals LLC1$17
Hologic Sales And Service, LLC1$16
Sanofi-aventis U.S. LLC1$16

How this compares

$906,889 in reported general payments places this provider in the 95th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island →

Medicare billing

Part B allowed, 2024
$48,142
Medicare patients
146
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Cumberland

See the full list for Rhode Island →

Where these figures come from

Is this you, or does something look wrong? →